FEF25%-75%

FEF25%–75%

Pulmonary medicine A clinical test that measures the forced expiratory flow from 25% to 75% of vital capacity, which was once thought to be one of the most sensitive, simplest, and least expensive methods for evaluating small airways disease
References in periodicals archive ?
Regression coefficients are provided for FVC, FEV1, FEV1/FVC, FEF25%-75%, and PEF (peak expiratory flow).
One exception to this finding is the predicted values for FEF25%-75% which tend to be slightly lower, at least in comparison to some older studies.
In the first study, the FEF25%-75% scores rose from a baseline average of 74.
However, there were no statistically significant differences between denufosol and placebo for three key secondary endpoints including rate of change in percent predicted FEV1 over 48 weeks, change from baseline in FEF25%-75% (Forced Expiratory Flow) at the week 48 endpoint and time to first pulmonary exacerbation.
In children, the forced expiratory flow over the middle half of forced vital capacity, or FEF25%-75%, is a more sensitive indicator of airflow obstruction than is [FEV.
The change from baseline for FEF25%-75% (Forced Expiratory Flow), a measure of small airways function, for the adolescent patients treated with denufosol at the Week 24 Endpoint was 115 mL/sec.
This was supported by a post-hoc analysis of the TIGER-1 trial data, which showed a significant improvement relative to placebo in FEF25%-75% in a subgroup of patients (n=329) with baseline FEV1 110% predicted normal (p=0.
The potential of denufosol to reach the lung's small airways was supported by a post-hoc analysis of the TIGER-1 trial, which showed a significant improvement relative to placebo in FEF25%-75% (Forced Expiratory Flow) in a subgroup of patients (n=329) with baseline FEV1 (Forced Expiratory Volume in One Second) [?